Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics

PURPOSE: The purpose of the study is to evaluate the effect of renal impairment (RI) and end-stage renal disease (ESRD) on the pharmacokinetics (PK) of isavuconazole and the inactive cleavage product, BAL8728. METHODS: A single intravenous dose of the prodrug isavuconazonium sulfate (372 mg, equival...

Descripción completa

Detalles Bibliográficos
Autores principales: Townsend, Robert W., Akhtar, Shahzad, Alcorn, Harry, Berg, Jolene K., Kowalski, Donna L., Mujais, Salim, Desai, Amit V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423998/
https://www.ncbi.nlm.nih.gov/pubmed/28271239
http://dx.doi.org/10.1007/s00228-017-2213-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423998/
https://www.ncbi.nlm.nih.gov/pubmed/28271239
http://dx.doi.org/10.1007/s00228-017-2213-7

Ejemplares similares